EUVIMEDEUVIMED entdecken
Open Access

A Text Messaging–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study

Natalie Levy iD, Katie Nerlino iD, Sherlane Bongalos iD, Alex Dasilva iD, Chinye Uzor iD, Ying Jie Liang iD, Olubunmi Sonubi iD

JMIR Formative Research · 09.04.2026 · 10 · e76993-e76993

DOI: 10.2196/76993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Formative Research, online erschienen am 09.04.2026. Verfasst von Natalie Levy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine and Clinical Innovation, NYU Grossman School of Medicine, OBV - A620, 462 First Avenue, New York, NY, 10016, Un…. Hauptthemen laut MEDLINE: Text Messaging, Diabetes Mellitus, Type 2, Insulin, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin both lower blood sugar, but while insulin puts people at risk of hypoglycemia and weight gain, GLP-1 RAs do not. In addition, GLP-1 RAs have added cardiometabolic and renal benefits. For these reasons, when possible, many primary care providers prefer their patients with well-controlled type 2 diabetes to be transitioned from basal insulin to a GLP-1 RA. This transition process can be labor intensive, requiring multiple dosing adjustments and a watchful eye for hypoglycemia and hyperglycemia. The Mobile Insulin Titration Intervention (MITI)–GLP1 program uses SMS text messaging–based technology to support a streamlined and supervised transition process from basal insulin to a GLP-1 RA. This program takes place at a multilingual safety-net clinic.

Objective

Our objectives were to assess program feasibility and acceptability to determine whether the intervention was doable, practical, and worthy of further investigation via a larger controlled trial. Preliminary clinical outcomes are also discussed in this paper.

Methods

Patients were enrolled on a secure web platform that sent them a daily SMS text message asking the following: “What was your fasting blood sugar this morning?” Each weekday, texted responses containing patients’ fasting blood sugar levels were checked for alarm values, and once weekly, patients were called and advised on whether and how to lower their basal insulin and increase their GLP-1 RA dose. The program was co-run by general internal medicine physicians and nurses and continued until the patient had their insulin stopped completely and/or their GLP-1 RA dose reached the maximum, or 16 weeks elapsed. All enrolled patients were included in the analyses.

Results

A total of 72 patients completed the pilot program. Feasibility and acceptability were high. Of 3671 SMS text messages sent by the program, 3520 (95.89%) received a response from patients. Of 719 cumulative weeks in which Thursday titration phone calls were attempted, successful connections with patients were made in 649 (90.26%) instances. Preliminary clinical outcomes were promising. Insulin doses were meaningfully reduced (55/72, 76.39% had their basal insulin reduced by at least 50%; 45/72, 62.5% had their insulin stopped completely). GLP-1 RA doses were meaningfully increased (64/72, 88.89% had their GLP-1 RA dose increased by ≥1 level; 45/72, 62.5% were discharged on the maximum dose of their GLP-1 RA). There was minimal hypoglycemia (5/3520, 0.14% of the SMS text messages reported a value of 400 mg/dL).

Conclusions

A general internal medicine–run MITI-GLP1 pilot program using SMS text messaging and interdisciplinary teamwork between internists and nurses is a feasible and acceptable intervention for safely and effectively transitioning people with well-controlled type 2 diabetes away from basal insulin and toward a GLP-1 RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Text MessagingDiabetes Mellitus, Type 2InsulinGlucagon-Like Peptide-1 Receptor AgonistsHumansPilot ProjectsFemaleMaleMiddle AgedAgedQuality ImprovementHypoglycemic AgentsSafety-net ProvidersAdultAdherence Interventions

Stichwörter der Autor:innen

GLP-1 receptor agonist dosingGLP-1 receptor agonistsSMS text messagingbasal insulinbasal insulin dosingdelivery of health careeHealthglucagon-like peptide-1 receptor agonist dosingglucagon-like peptide-1 receptor agonistshealth care disparitiesmHealthmobile healthprimary health caresafety netsocial drivers of health

Substanzen

InsulinGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of General Internal Medicine and Clinical Innovation, NYU Grossman School of Medicine, OBV - A620, 462 First Avenue, New York, NY, 10016, United States.
  • Department of Medicine, NYC Health + Hospital/Bellevue, New York, NY, United States.
  • Department of Nursing, NYC Health + Hospitals/Bellevue, New York, NY, United States.

ORCID-Profile: Natalie Levy, Katie Nerlino, Sherlane Bongalos, Alex Dasilva, Chinye Uzor, Ying Jie Liang, Olubunmi Sonubi

Zitieren

APA

Levy, N., Nerlino, K., Bongalos, S., Dasilva, A., Uzor, C., Liang, Y. J., & Sonubi, O. (2026). A Text Messaging–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study. JMIR Formative Research, 10, e76993-e76993. https://doi.org/10.2196/76993

Vancouver

Levy N, Nerlino K, Bongalos S, Dasilva A, Uzor C, Liang YJ, et al. A Text Messaging–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study. JMIR Formative Research. 2026;10:e76993-e76993. doi:10.2196/76993

BibTeX
@article{Levy2026,
  author = {Levy, Natalie and Nerlino, Katie and Bongalos, Sherlane and Dasilva, Alex and Uzor, Chinye and Liang, Ying Jie and Sonubi, Olubunmi},
  title = {A Text Messaging–Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study},
  journal = {JMIR Formative Research},
  year = {2026},
  volume = {10},
  pages = {e76993--e76993},
  doi = {10.2196/76993}
}
Kostenlos starten →